

Financial news for OXFD dated on 2020-06-05: The Daily Biotech Pulse: Adamas Rallies On FDA Acceptance, Oxford Immunotech Reportedly Gets \$400M Bid

Financial news for OXFD dated on 2020-05-19: The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces \$1.34B Common Stock Offering

Financial news for OXFD dated on 2020-05-06: 70 Biggest Movers From Yesterday

Financial news for OXFD dated on 2020-05-05: 51 Stocks Moving In Tuesday's Mid-Day Session

Financial news for OXFD dated on 2020-05-05: The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout

Financial news for OXFD dated on 2020-05-05: Recap: Oxford Immunotec Global Q1 Earnings

Financial news for OXFD dated on 2020-05-05: Oxford Immunotec Global Q1 EPS \$(0.230) Misses \$(0.150) Estimate, Sales \$13.900M Beat \$13.450M Estimate

Financial news for OXFD dated on 2020-05-03: The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace

Financial news for OXFD dated on 2020-03-19: The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latest Stage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection

Financial news for OXFD dated on 2020-03-17: The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment

Financial news for OXFD dated on 2020-03-13: The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings

Financial news for OXFD dated on 2020-03-12: Stocks That Hit 52-Week Lows On Thursday

Financial news for OXFD dated on 2020-03-12: The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO

Financial news for OXFD dated on 2020-03-10: The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index

Financial news for OXFD dated on 2020-03-02: Oxford Immunotec Global Q4 Sales \$18.1M Beat \$17.06M Estimate

Financial news for OXFD dated on 2020-02-20: Oxford Immunotec Highlights 2 Publications In 'Clinical Infectious Diseases' On Performance Of T-SPOT.CMV

Financial news for OXFD dated on 2020-01-21: 17 Diagnostics & Research Stocks Moving In Tuesday's Session

Financial news for OXFD dated on 2019-11-05: Oxford Immunotec Sees Q4 Sales \$16.4M-\$17.4M vs \$17.37M Est., Sees FY19 Sales \$72M-\$73M vs \$71.99M Est.

Financial news for OXFD dated on 2019-11-05: Oxford Immunotec Global Q3 EPS \$0.03 Beats \$(0.03) Estimate, Sales \$21.2M Beat \$20.31M Estimate

Financial news for OXFD dated on 2019-11-05: The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment

Financial news for OXFD dated on 2019-09-24: 46 Biggest Movers From Yesterday

Financial news for OXFD dated on 2019-09-23: Oxford Immunotec Global shares are trading higher following reports indicating the company is exploring strategic alternatives.

Financial news for OXFD dated on 2019-09-23: Oxford Immunotec Exploring Strategic Alternatives

Financial news for OXFD dated on 2019-08-07: 85 Biggest Movers From Yesterday

Financial news for OXFD dated on 2019-08-06: Oxford Immunotec Sees Q3 Sales \$20M-\$21M vs \$19.03M Est., Sales \$71M-\$73M vs \$70.57M Est.

Financial news for OXFD dated on 2019-08-06: Oxford Immunotec Global Q2 EPS \$0.02 Beats \$(0.04) Estimate, Sales \$19.6M Beat \$19.39M Estimate

Financial news for OXFD dated on 2019-05-09: The Daily Biotech Pulse: Novartis Goes Shopping, Mixed Trial Results For Provention Bio, 4 Stocks To Debut

Financial news for OXFD dated on 2019-05-09: Oxford Immunotec Global Q1 EPS \$(0.06) Beats \$(0.16) Estimate, Sales \$14.79M Beat \$13.82M Estimate

Financial news for OXFD dated on 2019-03-28: Oxford Immunotec Announces Initiative To Expand Its T-SPOT.TB Test In NOTE: Russia T-SPOT Received Russian Approval In 2013

Financial news for OXFD dated on 2019-03-21: Oxford Immunotec Appoints Matthew McLaughlin CFO

Financial news for OXFD dated on 2019-03-13: 56 Biggest Movers From Yesterday

Financial news for OXFD dated on 2019-03-12: 42 Stocks Moving In Tuesday's Mid-Day Session

Financial news for OXFD dated on 2019-03-12: Oxford Immunotec shares are trading higher after the company reported better-than-expected Q4 sales and provided FY19 sales guidance above analyst estimates.

Financial news for OXFD dated on 2019-03-12: The Daily Biotech Pulse: Zafgen Won't File IND For Metabolic Disorder Drug, Positive Results For Akebia's Anemia Drug

Financial news for OXFD dated on 2019-03-11: Oxford Immunotec Sees FY19 Sales \$69M-\$72M vs \$69.85M Est.

Financial news for OXFD dated on 2019-03-11: Oxford Immunotec Global Q4 EPS \$5.23 Does Not Compare To \$(0.19) Estimate, Sales \$15.37M Beat \$15.1M Estimate

Financial news for OXFD dated on 2019-03-10: The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings, IPOs

Financial news for OXFD dated on 2019-01-06: Oxford Immunotec Board Approves \$100M Share Repurchase Program and Reaffirms Growth Expectations for Fourth Quarter 2018 Ahead of J.P. Morgan Healthcare Conference

Financial news for OXFD dated on 2018-12-07: Oxford Immunotec Reports Regulatory Acceptance Of T-Cell Select In China

Financial news for OXFD dated on 2018-09-26: Stocks Which Set New 52-Week High Yesterday, September 25th

Financial news for OXFD dated on 2018-09-26: The Daily Biotech Pulse: Verastem's Chinese Duvelisib Licensing Deal, Aldeyra's Positive Dry Eye Disease Drug Trial

Financial news for OXFD dated on 2018-09-26: 51 Biggest Movers From Yesterday

Financial news for OXFD dated on 2018-09-25: 41 Stocks Moving In Tuesday's Mid-Day Session

Financial news for OXFD dated on 2018-09-25: Quest Diagnostics To Acquire U.S. Laboratory Services Business Of Oxford Immunotec

Financial news for OXFD dated on 2018-07-31: Oxford Immunotec Global PLC Shares Up 10% After Co. Announces Quarterly Financial Results; EPS \$(0.25), Inline, Sales \$29.318M Beat \$28.55M Estimate; Co. Also Announced Launch Of T-Cell Select In Europe

Financial news for OXFD dated on 2018-07-31: Oxford Immunotec Global Sees FY18 Sales \$112M-\$115M vs \$112.85M Est.

Financial news for OXFD dated on 2018-07-31: Oxford Immunotec Global Q2 EPS \$(0.25), Inline, Sales \$29.318M Beat \$28.55M Estimate

Financial news for OXFD dated on 2018-05-01: Oxford Immunotec Sees FY18 Sales \$112-\$115M vs \$112.3M Est.

Financial news for OXFD dated on 2018-05-01: Oxford Immunotec Q1 EPS \$(0.40) Beats \$(0.45) Est., Sales \$21.37M Beats \$20.9M Est.

Financial news for OXFD dated on 2018-02-27: Oxford Immunotec Reports Q4 EPS \$0.33 vs \$(0.22) In Prior Year Period, Sales \$25.02M vs \$23.70M In Prior Year Period

Financial news for OXFD dated on 2018-01-09: 48 Biggest Movers From Yesterday

Financial news for OXFD dated on 2018-01-08: 38 Stocks Moving In Monday's Mid-Day

## Session

Financial news for OXFD dated on 2018-01-08: Mid-Morning Market Update: Markets Down; Kohl's Raises Earnings Forecast

Financial news for OXFD dated on 2018-01-08: Oxford Immunotec Cuts Q4 Sales Guidance From \$25.4M-\$26.4M To \$24.9M-\$25.4M vs \$26.1M Est.; Narrows, Cuts FY17 Sales Guidance From \$103.5M-\$104.5M To \$103M-\$103.5M vs \$104.1M Est.

Financial news for OXFD dated on 2017-12-15: Oxford Immunotec, QIAGEN Report Settlement Of Patent Infringement Suit; All Claims Have Been Resolved; Oxford Has Granted QIAGEN Royalty-Free, Non-Exclusive License To All Current/Future Customers In Exchange For Lump-Sum Payment Of \$27.5M

Financial news for OXFD dated on 2017-11-01: 46 Biggest Movers From Yesterday

Financial news for OXFD dated on 2017-10-31: Oxford Immunotec Narrows FY17 Sales Outlook From \$103M-\$106M To \$103.5M-\$104.5M

Financial news for OXFD dated on 2017-10-31: Oxford Immunotec Sees Q4 Sales \$25.4M-\$26.4M vs \$27M Est.

Financial news for OXFD dated on 2017-10-31: Oxford Immunotec Reports Q3 EPS \$(0.70) vs \$(0.18) In Same Qtr. Last Year, Sales \$30.429M vs \$30.05M Est.

Financial news for OXFD dated on 2017-09-28: Benzinga's Top Upgrades, Downgrades For September 28, 2017

Financial news for OXFD dated on 2017-09-28: BTIG Research Initiates Coverage On Oxford Immunotec Global PLC - Ordinary Shares with Buy Rating, Announces \$21.00 Price Target

Financial news for OXFD dated on 2017-09-27: UPDATE: Oxford Immunotec Says 'We continue to look forward to the further defense of our patents at the upcoming trial in January'

Financial news for OXFD dated on 2017-09-27: Oxford Immunotec Global Offers Update In Patent Infringement Case: 'we are disappointed that the court did not grant a preliminary injunction prohibiting the sale of Qiagen's QFT-Plus product in the U.S. before trial'

Financial news for OXFD dated on 2017-08-30: Oxford Immunotec Names Stefan Linn COO

Financial news for OXFD dated on 2017-08-15: Oxford Immunotec Global Prices 2.5M Share Offering For Gross Proceeds \$40.125M

Financial news for OXFD dated on 2017-08-14: Oxford Immunotec Announces Offering 2.5M Shares Common Stock

Financial news for OXFD dated on 2017-08-01: Oxford Immunotec Sees Q3 Sales \$29.5-\$30.5M vs \$30.3M Est., FY17 Sales \$103-\$106M vs \$104.1M Est.

Financial news for OXFD dated on 2017-08-01: Oxford Immunotec Reports Q2 EPS \$(0.74) Does Not Compare To \$(0.32) Est., Sales \$26.12M vs \$25.05M Est.

Financial news for OXFD dated on 2017-06-15: Oxford Immunotec Global Reports Favorable Claim Construction Ruling Related To Patent Infringement Case

Financial news for OXFD dated on 2017-05-02: Oxford Immunotec Reports Q1 EPS \$(0.36) vs \$(0.35) Est., Sales \$21.5M vs \$21.2M Est.

Financial news for OXFD dated on 2017-02-28: Oxford Immunotec Sees Q1 Sales \$20.8-\$21.3M vs. \$22.6M Est., FY17 Sales \$102-\$105M vs. \$105M Est.

Financial news for OXFD dated on 2017-02-28: Oxford Immunotec Reports Q4 EPS \$(0.22) vs. \$(0.39) Est., Sales \$23.7M vs. \$22.9M Est.

Financial news for OXFD dated on 2017-01-11: JP Morgan Healthcare Conf. Continues Today; Presenters Include Novocure, Zoetis, Oxford Immunotec, Enanta, Irhythm Tech, Walgreen's, & Mylan

Financial news for OXFD dated on 2016-11-01: Immunotec Raises FY16 Rev. \$82.5-\$84.5M To \$85-\$85.8M

Financial news for OXFD dated on 2016-11-01: Oxford Immunotec Reports Q3 EPS \$(0.18) vs. Est. \$(0.33), Rev. \$26.1M vs. Est. \$24.7M

Financial news for OXFD dated on 2016-10-12: Oxford Immunotec Acquires Immunetics, Inc. For \$6M Cash And \$6M Cash Payable On Certain Rev. Thresholds and Milestones

Financial news for OXFD dated on 2016-10-03: Oxford Immunotec Reports Favorable Decision from U.S. District Court of Massachusetts in Patent Infringement Litigation

Financial news for OXFD dated on 2016-09-01: Oxford Immunotec Announces Favorable Recommendation by the Magistrate Judge in Patent Infringement Litigation

Financial news for OXFD dated on 2016-08-02: 18 Biggest Mid-Day Gainers For Tuesday

Financial news for OXFD dated on 2016-08-02: Top Performing Industries For August 2, 2016

Financial news for OXFD dated on 2016-08-02: Oxford Immunotec Reports Q2 EPS \$(0.29) vs. Est. \$(0.33), Rev. \$19.15M vs. Est. \$18.1M

Financial news for OXFD dated on 2016-06-23: Oxford Immunotec Raises FY16 Guidance From \$74M-\$77M To \$79.5M-\$82.5M

Financial news for OXFD dated on 2016-06-23: Oxford Immunotec Enters into Definitive Agreement to Acquire Imugen For \$22.2M All Cash

Financial news for OXFD dated on 2016-05-03: Oxford Immunotec Sees Q2 Sales \$17.4M-\$18.2M vs \$17.9M Est.; Sees FY16 Sales \$74M-\$77M vs \$76.2M Est.

Financial news for OXFD dated on 2016-05-03: Oxford Immunotec Reports Q1 EPS \$(0.32), Inline, Sales \$17.1M vs \$17M Est.

Financial news for OXFD dated on 2016-03-01: Oxford Immunotec Sees Q1 Sales \$16.6M-\$17.3M vs \$17.7M Est.; Sees FY16 Sales \$74M-\$77M vs \$79.7M Est.

Financial news for OXFD dated on 2016-03-01: Oxford Immunotec Reports Q4 EPS \$(0.29) vs \$(0.28) Est., Sales \$16.8M vs \$16.3M Est.

Financial news for OXFD dated on 2015-08-04: Oxford Immunotec Global Reports Q2 Revs \$14.3M Vs Est \$14.04M, Sees Q3 Revs \$16.8M-\$17.6M Vs Est \$17.44; Sees FY 2015 Revs \$61M-\$64M Vs Est \$62.12M

Financial news for OXFD dated on 2015-07-15: Oxford Immunotec Reports Exclusive Licensing Agreement With IDIBELL for B Cell Measurement, Technology Featured in Study Published in Kidney International

Financial news for OXFD dated on 2015-06-11: Oxford Immunotec Announces First Patient Enrolled in REACT Trial for T-SPOT.CMV

Financial news for OXFD dated on 2015-03-17: Oxford Immunotec Names Stephen M Gansler As SVP, Global Head Of Human Resources

Financial news for OXFD dated on 2015-02-05: Oxford Immunotec Announces First Patients Enrolled in PROTECT Trial for T-SPOT.CMV and T-SPOT.PRT

Financial news for OXFD dated on 2015-01-28: Oxford Immunotec Global PLC Announces Proposed Underwritten Offering of Ordinary Shares

Financial news for OXFD dated on 2015-01-06: Oxford Immunotec Announces Completion of Re-Registration in China for T-SPOT.TB Test

Financial news for OXFD dated on 2014-08-05: Oxford Immunotec To Acquire Assets From Boulder Diagnostic For \$7.9M

Financial news for OXFD dated on 2014-08-05: Oxford Immunotec Reports Q2 EPS of \$(0.36) Which May Not Compare \$(0.20) Est; Revenue of \$11.79M Which May Not Compare \$11.39M Est

Financial news for OXFD dated on 2014-05-19: 7 Stocks To Watch Ahead Of Lockup Expirations And PDUFA Dates

Financial news for OXFD dated on 2014-02-09: Financial Times Reports Large Number of US Biotech IPOs Could Indicate Bubble is Near

Financial news for OXFD dated on 2013-11-22: IPO of Oxford Immunotec Opens at \$14, Priced at \$12/Share

Financial news for OXFD dated on 2013-11-22: Oxford Immunotec Global Prices 5.36M Share IPO at \$12.00/Share

Financial news for OXFD dated on 2013-11-22: Oxford Immunotec Prices 5.36M Shares at \$12/Share in IPO